{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:05:42Z","timestamp":1770415542472,"version":"3.49.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010767","name":"Innovative Medicines Initiative","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.037","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T23:16:01Z","timestamp":1577142961000},"page":"1614-1622","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7075-421X","authenticated-orcid":false,"given":"Walter E.P.","family":"Beyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abraham M.","family":"Palache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leslie A.","family":"Reperant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimoun","family":"Boulfich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert D.M.E.","family":"Osterhaus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.037_b0005","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/erv.12.140","article-title":"The history of MF59\u00ae adjuvant: a phoenix that arose from the ashes","volume":"12","author":"O'Hagan","year":"2013","journal-title":"Exp Rev Vacc"},{"key":"10.1016\/j.vaccine.2019.12.037_b0010","unstructured":"Wikipedia, lemma \u2018Squalene\u2019. https:\/\/en.wikipedia.org\/wiki\/Squalene."},{"key":"10.1016\/j.vaccine.2019.12.037_b0015","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1016\/j.vaccine.2011.09.061","article-title":"The mechanism of action of MF59 - an innately attractive adjuvant formulation","volume":"30","author":"O'Hagan","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0020","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1016\/j.vaccine.2011.05.040","article-title":"Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis","volume":"29","author":"Beyer","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0025","doi-asserted-by":"crossref","first-page":"6959","DOI":"10.1016\/j.vaccine.2009.08.101","article-title":"MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database","volume":"27","author":"Pellegrini","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0030","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2515\/therapie\/2010069","article-title":"Safety review: squalene and thimerosal in vaccines","volume":"65","author":"Montana","year":"2010","journal-title":"Therapie"},{"key":"10.1016\/j.vaccine.2019.12.037_b0035","series-title":"Methods for Meta-Analysis in Medical Research","first-page":"58","author":"Sutton","year":"2000"},{"key":"10.1016\/j.vaccine.2019.12.037_b0040","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1016\/j.vaccine.2017.06.038","article-title":"Rationale for two influenza B lineages in seasonal vaccines: A meta-regression study on immunogenicity and controlled field trials","volume":"35","author":"Beyer","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0045","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-10-18","article-title":"Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model","volume":"10","author":"Coudeville","year":"2010","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.vaccine.2019.12.037_b0050","series-title":"Bootstrap Methods: A Guide for Practitioners and Researchers","author":"Chemick","year":"2008"},{"key":"10.1016\/j.vaccine.2019.12.037_b0055","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1016\/S0264-410X(99)00138-3","article-title":"Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly","volume":"17","author":"De Donato","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0060","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/INF.0000000000000465","article-title":"Dissecting the immune response to MF59-adjuvanted and nonadjuvanted seasonal influenza vaccines in children less than three years of age","volume":"34","author":"Zedda","year":"2015","journal-title":"Pediat Infect Dis J"},{"key":"10.1016\/j.vaccine.2019.12.037_b0065","first-page":"1799","article-title":"Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons","author":"Minutello","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0070","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.037_b0075","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/jmv.23630","article-title":"Long-term and cross-reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59-adjuvanted vaccine versus unadjuvanted vaccine","volume":"85","author":"Song","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2019.12.037_b0080","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.3390\/v4091438","article-title":"Evasion of influenza A viruses from innate and adaptive immune responses","volume":"4","author":"van de Sandt","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2019.12.037_b0085","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.vaccine.2015.11.058","article-title":"The confounded effects of age and exposure history in response to influenza vaccination","volume":"34","author":"Mosterin H\u00f6pping","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0090","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/CVI.00396-10","article-title":"Prevalence of antibodies against seasonal influenza A and B viruses in children in Netherlands","volume":"18","author":"Bodewes","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.12.037_b0095","doi-asserted-by":"crossref","unstructured":"Sauerbrei A, Langerhan T, Brandtstadt A, Schmidt-Ott R, Krumbholz A, et al. Prevalence of antibodies against influenza A and B viruses in children in Germany, 2008 to 2010. Euro Surveill 2014;19:pii: 20687.","DOI":"10.2807\/1560-7917.ES2014.19.5.20687"},{"key":"10.1016\/j.vaccine.2019.12.037_b0100","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2016.05.067","article-title":"H5N1 Vaccine Working Group. Extrapolating theoretical efficacy of inactivated influenza A\/H5N1 virus vaccine from human immunogenicity studies","volume":"34","author":"Feldstein","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0105","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/0264-410X(95)00240-2","article-title":"MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice","volume":"14","author":"Higgins","year":"1996","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0110","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1750-2659.2010.00183.x","article-title":"The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults","volume":"5","author":"Ambrose","year":"2011","journal-title":"Influenza Resp Vir"},{"key":"10.1016\/j.vaccine.2019.12.037_b0115","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.037_b0120","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1016\/j.vaccine.2017.07.003","article-title":"Basic principles of test-negative design in evaluating influenza vaccine effectiveness","volume":"35","author":"Fukushima","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0125","unstructured":"Rizzo C, Alfonsi V, Bollaerts K, Riera M, Stuurman A, Turunen T. Core protocol for type\/brand specific influenza vaccine effectiveness studies (test-negative design studies). Development of Robust and Innovative Vaccine Effectiveness (DRIVE) report 116134-2, 2018. https:\/\/www.drive-eu.org\/wp-content\/uploads\/2018\/12\/DRIVE_D7.1_Core-protocol-for-test-negative-design-studies_1.1.pdf."},{"key":"10.1016\/j.vaccine.2019.12.037_b0130","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.vaccine.2016.12.011","article-title":"Effectiveness of MF59-adjuvanted seasonal influenza vaccine in the elderly: A systematic review and meta-analysis","volume":"35","author":"Domnich","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.037_b0135","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1016\/j.vaccine.2013.07.059","article-title":"The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly","volume":"31","author":"Van Buynder","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:59Z","timestamp":1759401479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X19316792"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.037","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between vaccine adjuvant effect and pre-seasonal immunity. Systematic review and meta-analysis of randomised immunogenicity trials comparing squalene-adjuvanted and aqueous inactivated influenza vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}